oseltamivir has been researched along with elacridar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Fujita, T; Kanai, M; Kusuhara, H; Ose, A; Shibasaki, M; Sugiyama, Y; Yamamoto, A; Yamatsugu, K | 1 |
2 other study(ies) available for oseltamivir and elacridar
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Topics: Acetamides; Acridines; Animals; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Cell Line; Dogs; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Oseltamivir; Prodrugs; Rats; Rats, Wistar; RNA, Messenger; Swine; Tetrahydroisoquinolines | 2008 |